Skip to content
God Of Sound – Lifestyle
Author:
Verismo Therapeutics
Verismo Therapeutics Expands KIR-CAR Solid Tumor Treatment Pipeline with Novel Binder Developed at Penn Targeting Claudin 6 (CLDN6)
July 21, 2026
Verismo Therapeutics Presents Preclinical Data at AACR 2026 for SynKIR™-310 KIR-CAR Indicating Superior Preclinical Activity in B Cell Malignancies and Early Clinical Efficacy
April 21, 2026
Verismo Therapeutics’ Initial Clinical Data from STAR-101 Phase 1 Trial of SynKIR™-110 KIR-CAR Presented at AACR 2026 Plenary Session
April 20, 2026
Verismo Therapeutics Announces $28 Million Investment from HLB Innovation to Accelerate KIR-CAR Clinical Development
April 15, 2026
Verismo Therapeutics to Present Novel Multi-chain KIR-CAR Data – Including Initial Clinical Trial Results for Lead Immuno-Oncology Candidates SynKIR™-110 and SynKIR™-310 – at AACR Annual Meeting 2026
March 17, 2026